


## Supplementary material



**Supplemental Material, Figure S1:** Patient inclusion flow chart. In total, 3279 patients were presented in the hospital between 2014-2017. Among these, 1201 patients had an occlusion other than an MCA occlusion; 483 patients did not undergo EVT with a stent-retriever or aspiration device as a first-line approach; 122 had poor quality CTA scans; and 450 patients did not satisfy any of the three MCA occlusion patterns definitions. The abbreviations stand for: EVT, endovascular treatment; MCA, middle cerebral artery.

**Supplemental Material, Table S1:** MCA occlusion patterns for all 1023 patients. The occlusion patterns include MCA main stem, single branch, and double branch occlusions, as shown in Figure 1C.

<b>Main stem occlusions, n=370</b>				
Number of patients	Occluded segment			
	Proximal M1	Distal M1	Temporal M2	Frontoparietal M2
47	1	0	0	0
182	0	1	0	0
141	1	1	0	0
<b>Single branch occlusions, n=151</b>				
Number of patients	Occluded segment			
	Proximal M1	Distal M1	Temporal M2	Frontoparietal M2
36	0	1	1	0
69	0	1	0	1
27	1	1	1	0
19	1	1	0	1
<b>Double branch occlusions, n=502</b>				
Number of patients	Occluded segment			
	Proximal M1	Distal M1	Temporal M2	Frontoparietal M2
348	0	1	1	1
154	1	1	1	1

With 4 possible occlusion segments (proximal M1, distal M1, temporal M2 and frontoparietal M2), there are 16 possible combinations for the occlusion patterns. Some combinations are removed: 0000, non-occlusion; 1001, 1010 and 1011, non-continuous occlusions; 0010, 0001 and 0011, single and double branch occlusion patterns that do not include an M1 segment.

**Supplemental Material, Table S2:** Patient functional outcome.

Patient outcome	Main stem, n=370	Single branch, n=151	Double branch, n=502	p-value
NIHSS <sub>FU</sub> <sup>α</sup> – median (IQR)	<b>7 (2-15)</b>	<b>11 (4-17)</b>	<b>9 (4-16)</b>	<b>&lt;0.01</b>
ΔNIHSS <sup>β</sup> – median (IQR)	-6 (-11-(-1))	-4 (-9-0)	-5 (-10-0)	0.20
mRS at 90 days – no./total (%)				0.58
0	26/350 (7)	7/139 (5)	25/466 (5)	
1	69/350 (20)	22/139 (16)	79/466 (17)	
2	81/350 (23)	26/139 (19)	103/466 (22)	
3	37/350 (11)	17/139 (12)	66/466 (14)	
4	38/350 (11)	17/139 (12)	50/466 (11)	
5	18/350 (5)	14/139 (10)	28/466 (6)	
6	81/350 (23)	36/139 (26)	115/466 (25)	
sICH – no./total (%)	22/370 (6)	3/151 (2)	20/502 (4)	0.11

Missing values: <sup>α</sup>94, and <sup>β</sup>96.

ΔNIHSS, change in NIHSS score at 24-48h compared to baseline; NIHSS, National Institute of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage.

**Supplemental Material, Table S3:** Subgroup analysis of NIHSS<sub>FU</sub>, stratified by median age of the study population.

<b>Subgroup I: age ≤ 72 years</b>	<b>Main stem, n=213</b>	<b>Single branch, n=66</b>	<b>Double branch, n=241</b>	<b>p-value</b>
NIHSS <sub>FU</sub> <sup>α</sup> – median (IQR)	7 (2-12)	7 (3-15)	7 (3-13)	0.46
<b>Subgroup II: age &gt;72 years</b>	<b>Main stem, n=157</b>	<b>Single branch, n=85</b>	<b>Double branch, n=261</b>	
NIHSS <sub>FU</sub> <sup>β</sup> – median (IQR)	<b>8 (3-16)</b>	<b>13 (6-18)</b>	<b>11 (5-17)</b>	<b>0.03</b>

Missing values: <sup>α</sup>45, and <sup>β</sup>49.

FU, follow-up; IQR, interquartile range; NIHSS, National Institute of Health Stroke Scale.

**Subgroup analysis: first-line EVT approach**

**Supplemental Material, Table S4:** Subgroup analysis: patients treated with a stent-retriever as first-line device (n=750). Baseline characteristics, EVT outcomes, and functional outcomes of the three occlusion pattern groups.

Baseline characteristics	Main stem, n=268	Single branch, n=114	Double branch, n=368	p-value
Age – median (IQR)	70 (59-79)	73 (62-82)	72 (63-80)	0.11
Sex, female – no./total (%)	123/268 (46)	52/114 (46)	181/368 (49)	0.65
Medical history – no./total (%)				
Previous stroke	45/268 (17)	22/113 (19)	72/366 (20)	0.63
Diabetes mellitus	48/267 (18)	11/113 (10)	62/366 (17)	0.12
Hypertension	130/264 (49)	61/111 (55)	203/362 (56)	0.23
Atrial fibrillation	62/267 (23)	31/112 (28)	104/366 (28)	0.33
Pre-stroke mRS – no./total (%)				0.35
0	182/265 (69)	69/113 (61)	235/360 (65)	
1	36/265 (14)	19/113 (17)	47/360 (13)	
2	20/265 (7)	5/113 (4)	27/360 (8)	
≥3	27/265 (10)	20/113 (18)	51/360 (14)	
Systolic blood pressure <sup>α</sup> [mmHg] – median (IQR)	147 (128-164)	148 (130-165)	148 (130-162)	0.64
Diastolic blood pressure <sup>β</sup> [mmHg] – median (IQR)	80 (70-90)	80 (70-94)	80 (70-90)	0.96
NIHSS <sub>BL</sub> <sup>γ</sup> – median (IQR)	15 (10-19)	15 (12-19)	15 (12-19)	0.32
ASPECTS <sub>BL</sub> <sup>δ</sup> – median (IQR)	9 (8-10)	9 (8-10)	9 (7-10)	0.89
CS – no./total (%)				<0.01
0	<b>5/257 (2)</b>	<b>0/113 (0)</b>	<b>18/361 (5)</b>	
1	<b>54/257 (21)</b>	<b>41/113 (36)</b>	<b>131/361 (36)</b>	
2	<b>100/257 (39)</b>	<b>61/113 (54)</b>	<b>164/361 (45)</b>	
3	<b>98/257 (38)</b>	<b>11/113 (10)</b>	<b>48/361 (13)</b>	
CBS	<b>8 (6-8)</b>	<b>7 (5-7)</b>	<b>6 (4-6)</b>	<0.01
Treatment and workflow				
IVT – no./total (%)	201/268 (75)	81/114 (71)	259/368 (70)	0.47
Transferred patients – no./total (%)	137/268 (51)	67/114 (59)	200/368 (54)	0.38
Stroke onset* to first	56 (38-108)	52 (40-105)	58 (40-103)	0.97

hospital presentation <sup>ε</sup> [min] – median (IQR)				
Hospital presentation to IVT [min] <sup>ζ</sup> – median (IQR)	24 (19-30)	24 (19-35)	22 (17-33)	0.35
Stroke onset to groin puncture [min] – median (IQR)	197 (150-260)	217 (162-276)	195 (149-260)	0.12
<b>EVT outcomes</b>	<b>Main stem, n=268</b>	<b>Single branch, n=114</b>	<b>Double branch, n=368</b>	<b>p-value</b>
Procedural time <sup>η</sup> [min] – median (IQR)	58 (40-85)	60 (40-89)	62 (44-88)	0.54
Retrieval attempts – no./total (%)				0.36
1	104/253 (41)	49/109 (45)	126/351 (36)	
2	55/253 (22)	18/109 (17)	98/351 (28)	
3	46/253 (18)	20/109 (18)	60/351 (17)	
4	25/253 (10)	9/109 (8)	29/351 (8)	
≥5	23/253 (9)	13/109 (13)	38/351 (11)	
eTICI scores – no./total (%)				0.42
0	20/266 (8)	11/112 (10)	30/362 (8)	
1	12/266 (5)	7/112 (6)	8/362 (2)	
2A	47/266 (18)	22/112 (20)	82/362 (23)	
2B	59/266 (22)	21/112 (19)	80/362 (22)	
2C	30/266 (11)	10/112 (9)	47/362 (13)	
3	98/266 (37)	41/112 (36)	115/362 (32)	
ENT – no./total (%)	10/244 (4)	5/102 (5)	21/336 (6)	0.51
<b>Patient outcome</b>	<b>Main stem, n=268</b>	<b>Single branch, n=114</b>	<b>Double branch, n=368</b>	<b>p-value</b>
NIHSS <sub>FU</sub> <sup>θ</sup> – median (IQR)	<b>7 (2-15)</b>	<b>10 (4-17)</b>	<b>9 (4-15)</b>	<b>0.02</b>
ΔNIHSS <sup>ι</sup> – median (IQR)	-6 (-11-(-2))	-4 (-9-0)	-5 (-10-0)	0.19
mRS at 90 days – no./total (%)				0.73
0	19/255 (8)	6/106 (6)	17/345 (5)	
1	53/255 (21)	13/106 (12)	60/345 (17)	

2	57/255 (22)	21/106 (20)	74/345 (21)	
3	29/255 (11)	15/106 (14)	49/345 (14)	
4	26/255 (10)	14/106 (13)	40/345 (12)	
5	14/255 (6)	10/106 (9)	23/345 (7)	
6	57/255 (22)	27/106 (26)	82/345 (24)	
sICH – no./total (%)	<b>17/268 (6)</b>	<b>2/114 (2)</b>	<b>10/368 (3)</b>	<b>0.04</b>

Missing values: <sup>α</sup>13, <sup>β</sup>18, <sup>γ</sup>8, <sup>δ</sup>1, <sup>ε</sup>112, <sup>ζ</sup>305, <sup>η</sup>59, <sup>θ</sup>59, and <sup>ι</sup>60.

\*Time of stroke onset was defined as the time of witnessed symptom onset or, if unknown, as the time the patient was last seen well.

ΔNIHSS, change in NIHSS score at 24-48h compared to baseline; ASPECTS, Alberta Stroke Programme Early CT Score; BL, baseline; CBS, clot burden score; CS, collateral score; CT, computed tomography; ENT, embolization to new (previously unaffected) vascular territory; eTICI, expanded thrombolysis in cerebral infarction; EVT, endovascular treatment; IQR, interquartile range; IVT, intravenous treatment with alteplase; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage.

**Supplemental Material, Table S5:** Subgroup analysis: patients treated with aspiration as first-line device (n=273). Baseline characteristics, EVT outcomes, and functional outcomes of the three occlusion pattern groups.

Baseline characteristics	Main stem, n=102	Single branch, n=37	Double branch, n=134	p-value
Age – median (IQR)	69 (58-79)	76 (61-82)	74 (63-79)	0.28
Sex, female – no./total (%)	51/102 (50)	21/37 (57)	74/134 (55)	0.66
Medical history – no./total (%)				
Previous stroke	15/100 (15)	5/36 (14)	21/134 (16)	0.96
Diabetes mellitus	15/102 (15)	7/37 (19)	25/134 (19)	0.70
Hypertension	55/100 (55)	22/36 (61)	71/133 (53)	0.71
Atrial fibrillation	25/100 (25)	6/35 (17)	28/133 (21)	0.58
Pre-stroke mRS – no./total (%)				0.67
0	61/98 (62)	22/34 (65)	92/131 (70)	
1	21/98 (22)	6/34 (17)	16/131 (12)	
2	6/98 (6)	3/34 (9)	8/131 (6)	
≥3	10/98 (10)	3/34 (9)	15/131 (12)	
Systolic blood pressure <sup>α</sup> [mmHg] – median (IQR)	<b>156 (136-178)</b>	<b>149 (131-160)</b>	<b>145 (127-164)</b>	<b>0.04</b>
Diastolic blood pressure <sup>α</sup> [mmHg] – median (IQR)	<b>85 (77-95)</b>	<b>80 (70-88)</b>	<b>80 (70-90)</b>	<b>&lt;0.01</b>
NIHSS <sub>BL</sub> <sup>β</sup> – median (IQR)	15 (11-18)	16 (11-21)	16 (11-21)	0.31
ASPECTS <sub>BL</sub> – no./total (%)	9 (7-10)	9 (8-10)	9 (7-10)	0.52

CS – no./total (%)				<b>&lt;0.01</b>
0	<b>3/101 (3)</b>	<b>0/37 (0)</b>	<b>10/131 (8)</b>	
1	<b>21/101 (21)</b>	<b>15/37 (41)</b>	<b>48/131 (37)</b>	
2	<b>43/101 (43)</b>	<b>19/37 (51)</b>	<b>45/131 (34)</b>	
3	<b>34/101 (34)</b>	<b>3/37 (8)</b>	<b>28/131 (21)</b>	
CBS	<b>8 (6-8)</b>	<b>7 (5-7)</b>	<b>6 (4-6)</b>	<b>&lt;0.01</b>
Treatment and workflow				
IVT – no./total (%)	76/102 (75)	31/37 (84)	106/134 (79)	0.07
Transferred patients – no./total (%)	54/102 (53)	22/37 (59)	81/134 (60)	0.50
Stroke onset to first hospital presentation <sup>γ</sup> [min] – median (IQR)	52 (35-75)	62 (49-95)	55 (33-94)	0.45
Hospital presentation to IVT <sup>δ</sup> [min] – median (IQR)	<b>30 (20-37)</b>	<b>20 (17-27)</b>	<b>26 (20-34)</b>	<b>0.04</b>
Stroke onset to groin puncture [min] – median (IQR)	182 (145-244)	185 (148-235)	182 (139-246)	0.77
<b>EVT outcomes</b>	<b>Main stem, n=102</b>	<b>Single branch, n=37</b>	<b>Double branch, n=134</b>	<b>p-value</b>
Procedural time <sup>ε</sup> [min] – median (IQR)	50 (30-67)	46 (34-88)	42 (31-68)	0.53
Retrieval attempts – no./total (%)				0.23
1	42/90 (47)	18/35 (51)	68/125 (54)	
2	13/90 (14)	10/35 (29)	29/125 (23)	
3	15/90 (17)	4/35 (11)	12/125 (10)	
4	8/90 (9)	1/35 (3)	5/125 (4)	
≥5	12/90 (13)	2/35 (6)	11/125 (9)	
eTICI scores – no./total (%)				0.32
0	7/96 (7)	3/36 (8)	5/132 (4)	
1	2/96 (2)	0/36 (0)	0/132 (0)	
2A	25/96 (26)	8/36 (22)	23/132 (17)	
2B	14/96 (15)	10/36 (28)	27/132 (21)	



2C	13/96 (14)	4/36 (11)	20/132 (15)	
3	35/96 (36)	11/36 (31)	57/132 (43)	
ENT – no./total (%)	1/92 (1)	1/36 (3)	1/129 (1)	0.61
<b>Patient outcome</b>	<b>Main stem, n=102</b>	<b>Single branch, n=37</b>	<b>Double branch, n=134</b>	<b>p-value</b>
NIHSS <sub>FU</sub> <sup>ζ</sup> – median (IQR)	8 (3-14)	11 (5-17)	9 (4-17)	0.45
ΔNIHSS <sup>η</sup> – median (IQR)	-6 (-9-(-1))	-4 (-10-1)	-4 (-11-0)	0.84
mRS at 90 days – no./total (%)				0.54
0	7/95 (8)	1/33 (3)	8/121 (7)	
1	16/95 (17)	9/33 (27)	19/121 (16)	
2	24/95 (25)	5/33 (16)	29/121 (24)	
3	8/95 (8)	2/33 (6)	17/121 (14)	
4	12/95 (13)	3/33 (9)	10/121 (8)	
5	4/95 (4)	4/33 (12)	5/121 (4)	
6	24/95 (25)	9/33 (27)	33/121 (27)	
sICH – no./total (%)	5/102 (5)	1/37 (3)	10/134 (7)	0.48

Missing values: <sup>α</sup>13, <sup>β</sup>5, <sup>γ</sup>73, <sup>δ</sup>124, <sup>ε</sup>12, <sup>ζ</sup>35, and <sup>η</sup>36.

\*Time of stroke onset was defined as the time of witnessed symptom onset or, if unknown, as the time the patient was last seen well.

ΔNIHSS, change in NIHSS score at 24-48h compared to baseline; ASPECTS, Alberta Stroke Programme Early CT Score; BL, baseline; CBS, clot burden score; CS, collateral score; CT, computed tomography; ENT, embolization to new (previously unaffected) vascular territory; eTICI, expanded thrombolysis in cerebral infarction; EVT, endovascular treatment; IQR, interquartile range; IVT, intravenous treatment with alteplase; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage.

**Impact of proximal M1 occlusions**

**Supplemental Material, Table S6:** Subgroup analysis: impact of proximal M1 segments on main stem occlusions (n=370). Baseline characteristics, EVT outcomes, and functional outcomes for patients with an occluded vs. non-occluded proximal M1 segment.

Main stem Baseline characteristics	Occluded proximal M1, n=188	Non-occluded proximal M1, n=182	p-value
Age – median (IQR)	70 (59-81)	69 (59-79)	0.37
Sex, female – no./total (%)	83/188 (44)	91/182 (50)	0.26
Medical history – no./total (%)			
Previous stroke	30/187 (16)	30/181 (17)	0.89
Diabetes mellitus	32/187 (17)	31/182 (17)	0.98
Hypertension	98/187 (52)	87/177 (49)	0.54
Atrial fibrillation	44/187 (24)	43/180 (24)	0.94
Pre-stroke mRS – no./total (%)			0.09
0	122/184 (66)	121/179 (68)	
1	31/184 (17)	26/179 (14)	
2	8/184 (4)	18/179 (10)	
≥3	23/184 (13)	14/179 (8)	
Systolic blood pressure <sup>α</sup> [mmHg] – median (IQR)	150 (131-170)	149 (129-164)	0.20
Diastolic blood pressure <sup>β</sup> [mmHg] – median (IQR)	<b>83 (75-93)</b>	<b>80 (70-90)</b>	<b>0.05</b>
NIHSS <sub>BL</sub> <sup>γ</sup> – median (IQR)	<b>16 (12-20)</b>	<b>14 (10-17)</b>	<b>&lt;0.01</b>
ASPECTS <sub>BL</sub> <sup>δ</sup> – median (IQR)	<b>9 (7-10)</b>	<b>9 (8-10)</b>	<b>&lt;0.01</b>
CS – no./total (%)			0.47
0	5/181 (3)	3/177 (2)	
1	41/181 (23)	34/177 (19)	
2	75/181 (41)	68/177 (38)	
3	60/181 (33)	72/177 (41)	
Treatment and workflow			
IVT – no./total (%)	143/188 (76)	134/182 (74)	0.59
Transferred patients – no./total (%)	105/188 (56)	86/182 (47)	0.10
Stroke onset* to first hospital presentation <sup>ε</sup> [min] – median (IQR)	55 (39-104)	54 (37-105)	0.65
Hospital presentation to IVT [min] <sup>ζ</sup> – median (IQR)	24 (18-30)	25 (20-35)	0.07
Stroke onset to groin puncture [min] – median (IQR)	200 (151-255)	190 (145-256)	0.58
<b>Main stem EVT outcomes</b>			
Procedural time <sup>η</sup> [min] – median (IQR)	59 (40-78)	50 (35-80)	0.46

Retrieval attempts – no./total (%)			0.48
1	72/174 (41)	74/169 (44)	
2	31/174 (18)	37/169 (22)	
3	36/174 (21)	25/169 (15)	
4	19/174 (11)	14/169 (8)	
≥5	16/174 (9)	19/169 (11)	
eTICI scores – no./total (%)			0.23
0	14/186 (8)	13/176 (8)	
1	9/186 (5)	5/176 (3)	
2A	28/186 (15)	44/176 (25)	
2B	41/186 (22)	32/176 (18)	
2C	25/186 (13)	18/176 (10)	
3	69/186 (37)	64/176 (36)	
ENT – no./total (%)	6/173 (4)	5/163 (3)	0.84
<b>Main stem Patient outcome</b>	<b>Occluded proximal M1, n=188</b>	<b>Non-occluded proximal M1, n=182</b>	<b>p-value</b>
NIHSS <sub>FU</sub> <sup>0</sup> – median (IQR)	8 (2-15)	6 (2-14)	0.17
ΔNIHSS <sup>0</sup> – median (IQR)	-6 (-11-(-2))	-5 (-10-(-1))	0.20
mRS at 90 days – no./total (%)			0.25
0	14/176 (8)	12/174 (7)	
1	28/176 (16)	41/174 (24)	
2	37/176 (21)	44/174 (25)	
3	22/176 (12)	15/174 (9)	
4	22/176 (13)	16/174 (9)	
5	7/176 (4)	11/174 (6)	
6	46/176 (26)	35/174 (20)	
sICH – no./total (%)	14/188 (7)	8/182 (4)	0.22

Missing values: <sup>α</sup>10, <sup>β</sup>12, <sup>γ</sup>4, <sup>δ</sup>1, <sup>ε</sup>58, <sup>ζ</sup>143, <sup>η</sup>30, and <sup>θ</sup>40.

\*Time of stroke onset was defined as the time of witnessed symptom onset or, if unknown, as the time the patient was last seen well.

ΔNIHSS, change in NIHSS score at 24-48h compared to baseline; ASPECTS, Alberta Stroke Programme Early CT Score; BL, baseline; CS, collateral score; CT, computed tomography; ENT, embolization to new (previously unaffected) vascular territory; eTICI, expanded thrombolysis in cerebral infarction; EVT, endovascular treatment; IQR, interquartile range; IVT, intravenous treatment with alteplase; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage.

**Supplemental Material, Table S7:** Subgroup analysis: impact of proximal M1 segments on single branch occlusions (n=151). Baseline characteristics, EVT outcomes, and functional outcomes for patients with an occluded vs. non-occluded proximal M1 segment.

<b>Single branch Baseline characteristics</b>	<b>Occluded proximal M1, n=46</b>	<b>Non-occluded proximal M1, n=105</b>	<b>p-value</b>
Age – median (IQR)	73 (60-80)	74 (64-83)	0.31
Sex, female – no./total (%)	20/46 (44)	53/105 (51)	0.43
Medical history – no./total (%)			

Previous stroke	10/44 (23)	17/105 (16)	0.35
Diabetes mellitus	4/45 (9)	14/105 (13)	0.44
Hypertension	23/43 (54)	60/104 (58)	0.64
Atrial fibrillation	<b>6/44 (14)</b>	<b>31/103 (30)</b>	<b>0.04</b>
Pre-stroke mRS – no./total (%)			0.28
0	31/46 (67)	60/101 (59)	
1	7/46 (15)	18/101 (18)	
2	4/46 (9)	4/101 (4)	
≥3	4/46 (9)	19/101 (19)	
Systolic blood pressure <sup>α</sup> [mmHg] – median (IQR)	146 (130-165)	149 (131-164)	0.85
Diastolic blood pressure <sup>α</sup> [mmHg] – median (IQR)	80 (70-90)	80 (70-90)	0.99
NIHSS <sub>BL</sub> <sup>β</sup> – median (IQR)	<b>17 (14-20)</b>	<b>15 (12-18)</b>	<b>0.03</b>
ASPECTS <sub>BL</sub> – median (IQR)	9 (7-10)	9 (8-10)	0.51
CS – no./total (%)			0.54
0	0/45 (0)	0/105 (0)	
1	16/45 (36)	40/105 (38)	
2	23/45 (51)	57/105 (54)	
3	6/45 (13)	8/105 (8)	
Treatment and workflow			
IVT – no./total (%)	34/46 (74)	78/105 (74)	0.79
Transferred patients – no./total (%)	29/46 (63)	60/105 (57)	0.50
Stroke onset* to first hospital presentation <sup>γ</sup> [min] – median (IQR)	59 (45-95)	55 (40-110)	0.83
Hospital presentation to IVT [min] <sup>δ</sup> – median (IQR)	23 (16-33)	24 (18-33)	0.81
Stroke onset to groin puncture [min] – median (IQR)	195 (155-263)	210 (161-283)	0.25
<b>Single branch EVT outcomes</b>	<b>Occluded proximal M1, n=46</b>	<b>Non-occluded proximal M1, n=105</b>	<b>p-value</b>
Procedural time <sup>ε</sup> [min] – median (IQR)	60 (35-85)	56 (40-90)	0.69
Retrieval attempts – no./total (%)			0.92
1	18/43 (42)	49/101 (49)	
2	10/43 (23)	18/101 (18)	
3	8/43 (19)	16/101 (16)	
4	3/43 (7)	7/101 (7)	
≥5	4/43 (9)	11/101 (11)	
eTICI scores – no./total (%)			<b>0.05</b>
0	<b>5/44 (12)</b>	<b>9/104 (9)</b>	
1	<b>5/44 (11)</b>	<b>2/104 (2)</b>	
2A	<b>4/44 (9)</b>	<b>26/104 (25)</b>	

2B	<b>11/44 (25)</b>	<b>20/104 (19)</b>	
2C	<b>5/44 (11)</b>	<b>9/104 (9)</b>	
3	<b>14/44 (32)</b>	<b>38/104 (36)</b>	
ENT – no./total (%)	1/42 (2)	5/96 (5)	0.45
<b>Single branch Patient outcome</b>	<b>Occluded proximal M1, n=46</b>	<b>Non-occluded proximal M1, n=105</b>	<b>p-value</b>
NIHSS <sub>FU</sub> <sup>ζ</sup> – median (IQR)	10 (5-16)	11 (4-17)	0.77
ΔNIHSS <sup>η</sup> – median (IQR)	-7 (-11-(-1))	-4 (-9-0)	0.07
mRS at 90 days – no./total (%)			0.80
0	2/42 (5)	5/97 (5)	
1	8/42 (19)	14/97 (14)	
2	8/42 (19)	18/97 (19)	
3	4/42 (10)	13/97 (14)	
4	3/42 (7)	14/97 (14)	
5	6/42 (14)	8/97 (8)	
6	11/42 (26)	25/97 (26)	
sICH – no./total (%)	1/146 (2)	2/105 (2)	0.91

Missing values: <sup>α</sup>2, <sup>β</sup>5, <sup>γ</sup>30, <sup>δ</sup>68, <sup>ε</sup>4, <sup>ζ</sup>13, and <sup>η</sup>14.

\*Time of stroke onset was defined as the time of witnessed symptom onset or, if unknown, as the time the patient was last seen well.

ΔNIHSS, change in NIHSS score at 24-48h compared to baseline; ASPECTS, Alberta Stroke Programme Early CT Score; BL, baseline; CS, collateral score; CT, computed tomography; ENT, embolization to new (previously unaffected) vascular territory; eTICI, expanded thrombolysis in cerebral infarction; EVT, endovascular treatment; IQR, interquartile range; IVT, intravenous treatment with alteplase; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage.

**Supplemental Material, Table S8:** Subgroup analysis: impact of proximal M1 segments on double branch occlusions (n=502). Baseline characteristics, EVT outcomes, and functional outcomes for patients with an occluded vs. non-occluded proximal M1 segment.

<b>Double branch Baseline characteristics</b>	<b>Occluded proximal M1, n=154</b>	<b>Non-occluded proximal M1, n=348</b>	<b>p-value</b>
Age – median (IQR)	72 (64-80)	73 (62-80)	0.52
Sex, female – no./total (%)	82/154 (53)	173/348 (50)	0.47
Medical history – no./total (%)			
Previous stroke	31/154 (20)	62/346 (18)	0.56
Diabetes mellitus	28/154 (18)	59/346 (17)	0.76
Hypertension	88/152 (58)	186/343 (54)	0.45
Atrial fibrillation	36/153 (24)	96/346 (28)	0.33
Pre-stroke mRS – no./total (%)			0.16
0	107/149 (72)	220/342 (64)	
1	12/149 (8)	51/342 (15)	
2	12/149 (8)	23/342 (7)	
≥3	18/149 (12)	48/342 (14)	

Systolic blood pressure <sup>α</sup> [mmHg] – median (IQR)	<b>150 (135-165)</b>	<b>144 (127-160)</b>	<b>0.02</b>
Diastolic blood pressure <sup>β</sup> [mmHg] – median (IQR)	81 (70-90)	80 (72-90)	0.38
NIHSS <sub>BL</sub> <sup>γ</sup> – median (IQR)	<b>17 (13-20)</b>	<b>15 (11-19)</b>	<b>&lt;0.01</b>
ASPECTS <sub>BL</sub> – median (IQR)	<b>9 (7-10)</b>	<b>9 (8-10)</b>	<b>&lt;0.01</b>
CS – no./total (%)			0.13
0	9/148 (6)	19/344 (6)	
1	65/148 (44)	114/344 (33)	
2	54/148 (37)	155/344 (45)	
3	20/148 (13)	56/344 (16)	
Treatment and workflow			
IVT – no./total (%)	117/154 (76)	248/348 (71)	0.43
Transferred patients – no./total (%)	86/154 (56)	195/348 (56)	0.97
Stroke onset* to first hospital presentation <sup>δ</sup> [min] – median (IQR)	59 (40-110)	56 (37-99)	0.45
Hospital presentation to IVT [min] <sup>ε</sup> – median (IQR)	22 (19-34)	24 (17-33)	0.87
Stroke onset to groin puncture [min] – median (IQR)	193 (147-246)	192 (147-260)	0.69
<b>Double branch EVT outcomes</b>	<b>Occluded proximal M1, n=154</b>	<b>Non-occluded proximal M1, n=348</b>	<b>p-value</b>
Procedural time <sup>ζ</sup> [min] – median (IQR)	55 (35-85)	57 (40-83)	0.59
Retrieval attempts – no./total (%)			0.72
1	64/148 (43)	130/328 (40)	
2	37/148 (25)	90/328 (27)	
3	19/148 (13)	53/328 (16)	
4	10/148 (7)	24/328 (7)	
≥5	18/148 (12)	31/328 (10)	
eTICI scores – no./total (%)			<b>0.04</b>
0	<b>13/153 (9)</b>	<b>22/341 (7)</b>	
1	<b>4/153 (3)</b>	<b>4/341 (1)</b>	
2A	<b>19/153 (12)</b>	<b>86/341 (25)</b>	
2B	<b>34/153 (22)</b>	<b>73/341 (21)</b>	
2C	<b>24/153 (16)</b>	<b>43/341 (13)</b>	
3	<b>59/153 (39)</b>	<b>113/341 (33)</b>	
ENT – no./total (%)	7/145 (5)	15/320 (5)	0.95
<b>Double branch Patient outcome</b>	<b>Occluded proximal M1, n=154</b>	<b>Non-occluded proximal M1, n=348</b>	<b>p-value</b>
NIHSS <sub>FU</sub> <sup>η</sup> – median (IQR)	<b>11 (5-17)</b>	<b>8 (3-15)</b>	<b>0.01</b>
ΔNIHSS <sup>θ</sup> – median (IQR)	-5 (-10-0)	-5 (-10-(-1))	0.90

mRS at 90 days – no./total (%)			0.17
0	2/144 (1)	23/322(7)	
1	24/144 (17)	55/322 (17)	
2	28/144 (19)	75/322 (23)	
3	21/144 (15)	45/322 (14)	
4	19/144 (13)	31/322 (10)	
5	10/144 (7)	18/322 (6)	
6	40/144 (28)	75/322 (23)	
sICH – no./total (%)	9/154 (6)	11/348 (3)	0.16

Missing values: <sup>α</sup>14, <sup>β</sup>17, <sup>γ</sup>4, <sup>δ</sup>97, <sup>ε</sup>218, <sup>ζ</sup>37, <sup>η</sup>41, and <sup>θ</sup>42.

\*Time of stroke onset was defined as the time of witnessed symptom onset or, if unknown, as the time the patient was last seen well.

ΔNIHSS, change in NIHSS score at 24-48h compared to baseline; ASPECTS, Alberta Stroke Programme Early CT Score; BL, baseline; CS, collateral score; CT, computed tomography; ENT, embolization to new (previously unaffected) vascular territory; eTICI, expanded thrombolysis in cerebral infarction; EVT, endovascular treatment; IQR, interquartile range; IVT, intravenous treatment with alteplase; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage.

**MR CLEAN Registry investigators – Group author****Executive committee**

Diederik W.J. Dippel<sup>1</sup>; Aad van der Lugt<sup>2</sup>; Charles B.L.M. Majoie<sup>3</sup>; Yvo B.W.E.M. Roos<sup>4</sup>; Robert J. van Oostenbrugge<sup>5</sup>; Wim H. van Zwam<sup>6</sup>; Jelis Boiten<sup>14</sup>; Jan Albert Vos<sup>8</sup>.

**Study coordinators**

Ivo G.H. Jansen<sup>3</sup>; Maxim J.H.L. Mulder<sup>1,2</sup>; Robert- Jan B. Goldhoorn<sup>5,6</sup>; Kars C.J. Compagne<sup>2</sup>; Manon Kappelhof<sup>3</sup>; Josje Brouwer<sup>4</sup>; Sanne J. den Hartog<sup>1,2,40</sup>; Wouter H. Hinsenveld<sup>5,6</sup>.

**Local principal investigators**

Diederik W.J. Dippel<sup>1</sup>; Bob Roozenbeek<sup>1</sup>; Aad van der Lugt<sup>2</sup>; Adriaan C.G.M. van Es<sup>2</sup>; Charles B.L.M. Majoie<sup>3</sup>; Yvo B.W.E.M. Roos<sup>4</sup>; Bart J. Emmer<sup>3</sup>; Jonathan M. Coutinho<sup>4</sup>; Wouter J. Schonewille<sup>7</sup>; Jan Albert Vos<sup>8</sup>; Marieke J.H. Wermer<sup>9</sup>; Marianne A.A. van Walderveen<sup>10</sup>; Julie Staals<sup>5</sup>; Robert J. van Oostenbrugge<sup>5</sup>; Wim H. van Zwam<sup>6</sup>; Jeannette Hofmeijer<sup>11</sup>; Jasper M. Martens<sup>12</sup>; Geert J. Lycklama à Nijeholt<sup>13</sup>; Jelis Boiten<sup>14</sup>; Sebastiaan F. de Bruijn<sup>15</sup>; Lukas C. van Dijk<sup>16</sup>; H. Bart van der Worp<sup>17</sup>; Rob H. Lo<sup>18</sup>; Ewoud J. van Dijk<sup>19</sup>; Hieronymus D. Boogaarts<sup>20</sup>; J. de Vries<sup>22</sup>; Paul L.M. de Kort<sup>21</sup>; Julia van Tuijl<sup>21</sup>; Jo P. Peluso<sup>26</sup>; Puck Fransen<sup>22</sup>; Jan S.P. van den Berg<sup>22</sup>; Boudewijn A.A.M. van Hasselt<sup>23</sup>; Leo A.M. Aerden<sup>24</sup>; René J. Dallinga<sup>25</sup>; Maarten Uyttenboogaart<sup>28</sup>; Omid Eschgi<sup>29</sup>; Reinoud P.H. Bokkers<sup>29</sup>; Tobien H.C.M.L. Schreuder<sup>30</sup>; Roel J.J. Heijboer<sup>31</sup>; Koos Keizer<sup>32</sup>; Lonke S.F. Yo<sup>33</sup>; Heleen M. den Hertog<sup>22</sup>; Tomas Bulut<sup>35</sup>; Paul J.A.M. Brouwers<sup>34</sup>.

**Imaging assessment committee**

Charles B.L.M. Majoie<sup>3</sup> (chair); Wim H. van Zwam<sup>6</sup>; Aad van der Lugt<sup>2</sup>; Geert J. Lycklama à Nijeholt<sup>13</sup>; Marianne A.A. van Walderveen<sup>10</sup>; Marieke E.S. Sprengers<sup>3</sup>; Sjoerd F.M. Jenniskens<sup>27</sup>; René van den Berg<sup>3</sup>; Albert J. Yoo<sup>38</sup>; Ludo F.M. Beenen<sup>3</sup>; Alida A. Postma<sup>6</sup>; Stefan D. Roosendaal<sup>3</sup>; Bas F.W. van der Kallen<sup>13</sup>; Ido R. van den Wijngaard<sup>13</sup>; Adriaan C.G.M. van Es<sup>2</sup>; Bart J. Emmer<sup>3</sup>; Jasper M. Martens<sup>12</sup>; Lonke S.F. Yo<sup>33</sup>; Jan Albert Vos<sup>8</sup>; Joost Bot<sup>36</sup>; Pieter-Jan van Doormaal<sup>2</sup>; Anton Meijer<sup>27</sup>; Elyas Ghariq<sup>13</sup>; Reinoud P.H. Bokkers<sup>29</sup>; Marc P. van Proosdij<sup>37</sup>; G. Menno Krietemeijer<sup>33</sup>; Jo P. Peluso<sup>26</sup>; Hieronymus D. Boogaarts<sup>20</sup>; Rob Lo<sup>18</sup>; Wouter Dinkelaar<sup>2</sup>; Auke P.A. Appelman<sup>29</sup>; Bas Hammer<sup>16</sup>; Sjoert Pegge<sup>27</sup>; Anouk van der Hoorn<sup>29</sup>; Saman Vinke<sup>20</sup>.

**Writing committee**

Diederik W.J. Dippel<sup>1</sup> (chair); Aad van der Lugt<sup>2</sup>; Charles B.L.M. Majoie<sup>3</sup>; Yvo B.W.E.M. Roos<sup>4</sup>; Robert J. van Oostenbrugge<sup>5</sup>; Wim H. van Zwam<sup>6</sup>; Geert J. Lycklama à Nijeholt<sup>13</sup>; Jelis Boiten<sup>14</sup>; Jan Albert Vos<sup>8</sup>; Wouter J. Schonewille<sup>7</sup>; Jeannette Hofmeijer<sup>11</sup>; Jasper M. Martens<sup>12</sup>; H. Bart van der Worp<sup>17</sup>; Rob H. Lo<sup>18</sup>.

**Adverse event committee**

Robert J. van Oostenbrugge<sup>5</sup> (chair); Jeannette Hofmeijer<sup>11</sup>; H. Zwenneke Flach<sup>23</sup>.

**Trial methodologist**

Hester F. Lingsma<sup>40</sup>.

**Research nurses / local trial coordinators**



Naziha el Ghannouti<sup>1</sup>; Martin Sterrenberg<sup>1</sup>; Wilma Pellikaan<sup>7</sup>; Rita Sprengers<sup>4</sup>; Marjan Elfrink<sup>11</sup>; Michelle Simons<sup>11</sup>; Marjolein Vossers<sup>12</sup>; Joke de Meris<sup>14</sup>; Tamara Vermeulen<sup>14</sup>; Annet Geerlings<sup>19</sup>; Gina van Vemde<sup>22</sup>; Tiny Simons<sup>30</sup>; Gert Messchendorp<sup>28</sup>; Nynke Nicolaij<sup>28</sup>; Hester Bongenaar<sup>32</sup>; Karin Bodde<sup>24</sup>; Sandra Kleijn<sup>34</sup>; Jasmijn Lodico<sup>34</sup>; Hanneke Droste<sup>34</sup>; Maureen Wollaert<sup>5</sup>; Sabrina Verheesen<sup>5</sup>; D. Jeurissen<sup>5</sup>; Erna Bos<sup>9</sup>; Yvonne Drabbe<sup>15</sup>; Michelle Sandiman<sup>15</sup>; Noline Aaldering<sup>11</sup>; Berber Zweedijk<sup>17</sup>; Jocova Vervoort<sup>21</sup>; Eva Ponjee<sup>22</sup>; Sharon Romviel<sup>19</sup>; Karin Kanselaar<sup>19</sup>; Denn Barning<sup>10</sup>.

#### PhD / Medical students:

Esmee Venema<sup>40</sup>; Vicky Chalos<sup>1,40</sup>; Ralph R. Geuskens<sup>3</sup>; Tim van Straaten<sup>19</sup>; Saliha Ergezen<sup>1</sup>; Roger R.M. Harmsma<sup>1</sup>; Daan Muijres<sup>1</sup>; Anouk de Jong<sup>1</sup>; Olvert A. Berkhemer<sup>1,3,6</sup>; Anna M.M. Boers<sup>3,39</sup>; J. Huguet<sup>3</sup>; P.F.C. Groot<sup>3</sup>; Marieke A. Mens<sup>3</sup>; Katinka R. van Kranendonk<sup>3</sup>; Kilian M. Treurniet<sup>3</sup>; Manon L. Tolhuisen<sup>3,39</sup>; Heitor Alves<sup>3</sup>; Annick J. Weterings<sup>3</sup>; Eleonora L.F. Kirkels<sup>3</sup>; Eva J.H.F. Voogd<sup>11</sup>; Lieve M. Schupp<sup>3</sup>; Sabine L. Collette<sup>28,29</sup>; Adrien E.D. Groot<sup>4</sup>; Natalie E. LeCouffe<sup>4</sup>; Praneeta R. Konduri<sup>39</sup>; Haryadi Prasetya<sup>39</sup>; Nerea Arrarte-Terreros<sup>39</sup>; Lucas A. Ramos<sup>39</sup>.

#### List of affiliations

Department of Neurology<sup>1</sup>, Radiology<sup>2</sup>, Public Health<sup>40</sup>, Erasmus MC University Medical Center;

Department of Radiology and Nuclear Medicine<sup>3</sup>, Neurology<sup>4</sup>, Biomedical Engineering & Physics<sup>39</sup>, Amsterdam UMC, University of Amsterdam, Amsterdam;

Department of Neurology<sup>5</sup>, Radiology<sup>6</sup>, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM);

Department of Neurology<sup>7</sup>, Radiology<sup>8</sup>, Sint Antonius Hospital, Nieuwegein;

Department of Neurology<sup>9</sup>, Radiology<sup>10</sup>, Leiden University Medical Center;

Department of Neurology<sup>11</sup>, Radiology<sup>12</sup>, Rijnstate Hospital, Arnhem;

Department of Radiology<sup>13</sup>, Neurology<sup>14</sup>, Haaglanden MC, the Hague;

Department of Neurology<sup>15</sup>, Radiology<sup>16</sup>, HAGA Hospital, the Hague;

Department of Neurology<sup>17</sup>, Radiology<sup>18</sup>, University Medical Center Utrecht;

Department of Neurology<sup>19</sup>, Neurosurgery<sup>20</sup>, Radiology<sup>27</sup>, Radboud University Medical Center, Nijmegen;

Department of Neurology<sup>21</sup>, Radiology<sup>26</sup>, Elisabeth-TweeSteden ziekenhuis, Tilburg;

Department of Neurology<sup>22</sup>, Radiology<sup>23</sup>, Isala Klinieken, Zwolle;

Department of Neurology<sup>24</sup>, Radiology<sup>25</sup>, Reinier de Graaf Gasthuis, Delft;

Department of Neurology<sup>28</sup>, Radiology<sup>29</sup>, University Medical Center Groningen;

Department of Neurology<sup>30</sup>, Radiology<sup>31</sup>, Atrium Medical Center, Heerlen;

Department of Neurology<sup>32</sup>, Radiology<sup>33</sup>, Catharina Hospital, Eindhoven;

Department of Neurology<sup>34</sup>, Radiology<sup>35</sup>, Medisch Spectrum Twente, Enschede;

Department of Radiology<sup>36</sup>, Amsterdam UMC, Vrije Universiteit van Amsterdam, Amsterdam;

Department of Radiology<sup>37</sup>, Noordwest Ziekenhuisgroep, Alkmaar;

Department of Radiology<sup>38</sup>, Texas Stroke Institute, Texas, United States of America.